Application of dlk1 gene in preparation of diagnostic reagent for gastrointestinal stromal tumor

Abstract

The invention relates to application of a DLK1 (delta drosophila homolog-like1) gene in preparation of a gastrointestinal stromal tumor diagnostic reagent. The new discovery of the invention can be applied to development of drugs or kits based on RT-PCR, PCR, immunodetection, in-situ hybridization, gene chip and other technologies for diagnosis of gastrointestinal stromal tumors. The invention puts forward for the first time that detection based on DLK1 gene and its products in serum / tissue can be utilized to achieve early diagnosis of GIST or carry out prognosis on GIST patients undergoing surgical treatment, the high-throughput chip screening + real-time quantitative PCR validation established on the gene level and large sample clinical sample validation on the protein level have reliable result, and DLK1 can significantly distinguish tumors and nontumors, high-risk tumors and low-risk tumors both on the gene level and protein level, and the result repeatability is good. Thus, DLK1 gene has good clinical application value.

Description

technical field [0001] The invention belongs to the field of biomedicine; more specifically, the invention relates to the application of DLK1 gene in the preparation of diagnostic reagents for gastrointestinal stromal tumors. Background technique [0002] Gastrointestinal stromal tumor (GIST) is the most common tumor of mesenchymal origin in the gastrointestinal tract, mainly occurring in the stomach (about 70%). In recent years, the incidence of GIST has been increasing rapidly year by year. The previous epidemiological data showed that the incidence of GIST was about 7-15 / million people / year. In recent years, the incidence of GIST has exceeded 20 / hundred 10,000 people / year. In 2009, the epidemiological survey data in China showed that the incidence rate reached about 30 / million people / year. It is estimated that the number of new cases in China every year can reach about 40,000-50,000. GIST has become the most common malignant tumor in the digestive tract after gastric c...

AI Technical Summary

Problems solved by technology

However, there are also some problems in the clinical practice of targeted drug therapy: (1) about 5-10% of patients are primary resistant to imatinib, and most of the patients who are effective to initial treatment with imatinib Patients will inevitably develop drug resistance eventually, and drug resistance mostly occurs within 6 months to 2 years after the initiation of initial treatment; (2) Currently, patients with high recurrence risk of GIST receive adjuvant imatinib therapy for a certain period of time after surgery. Consensus has been reached, however, the selection of the appropriate population for adjuvant therapy has always been controversial. Relaxing the indications for treatment will inevitably lead to a waste of medical resources and increase the occurrence of drug resistance; excessively strict indications will also cause some patients to miss the reasonable treatment they should receive (3) The high price of imatinib discourages many patients. If there are more objective and reasonable indicators for judging the recurrence risk of GIST patients, it will greatly benefit the rational allocation of medical resources

Images